Ten years of progress in our understanding of uremic vascular calcification and disease: a decade summarized in 20 steps  by Brandenburg, Vincent M. et al.
Ten years of progress in our understanding
of uremic vascular calcification and disease:
a decade summarized in 20 steps
Vincent M. Brandenburg1, Markus Ketteler2 and Mariano Rodriguez3
1Department of Cardiology, University Hospital Aachen, Aachen, Germany and 2Department of Nephrology, Klinikum Coburg,
Coburg, Germany and 3Nephrology Services, Hospital Universitario Reina Sofia (IMIBIC), Cordoba, Spain
Accelerated vascular calcification is a hallmark of patients
with chronic kidney disease (CKD) and contributes
substantially to the enormous disease burden and high
mortality in these patients. Within the last 10 years, many
authors have significantly contributed to the progress that
has been made in our understanding of how important the
problem of vascular calcification is for CKD and end-stage
renal disease patients. In parallel, our knowledge has
substantially increased about the pathophysiology of
vascular disease. In consequence, dialysis patient care has
undergone significant changes in the last decade. Our review
focuses on publications on vascular health in uremia during
the period 2000–2010, and we have chosen 20 landmark
publications out of this decade that help us to summarize the
increasing knowledge on this issue. Two guidelines (Kidney
Disease Outcomes Quality Initiative 2003 and Kidney Disease:
Improving Global Outcomes 2009) have been published
with a strong focus upon bone, mineral, and cardiovascular
disorders. These 20 publications highlight in a chronological
step-by-step approach the developments and progress
that have been made in the field of ‘vascular calcification
in uremia’. This subjective review of selected contributions
attempts to bridge the gap from basic science data about
the role of phosphate, Klotho, and vitamin D to vascular
wall biology, and integrates clinical and epidemiological
data, which have substantially influenced CKD patient
care regarding vascular health.
Kidney International Supplements (2011) 1, 116–121; doi:10.1038/kisup.2011.27
KEYWORDS: adynamic bone disease; bone–vascular axis; calcification;
chronic kidney disease–mineral and bone disorder; hyperparathyroidism;
phosphate
TO CITE THIS ARTICLE:
Brandenburg VM, Ketteler M, Rodriguez M. Ten years of progress in our
understanding of uremic vascular calcification and disease: a decade
summarized in 20 steps. Kidney inter., Suppl. 2011; 1: 116–121.
The last decade has brought a massive increase in our under-
standing of how important cardiovascular disease is for
patients with chronic kidney disease (CKD). Cardiovascular
disease in CKD is not just a highly prevalent copy of what can
be found in the general population. It is rather a particular
disease with a special composition and distinct features,
respectively, regarding risk factors, clinical, and pathological
findings, as well as outcome. Although first reports about this
deleterious association of chronic kidney and cardiovascular
disease emerged as early as 40 years ago, it was only a little
over a decade ago that the true dimension of the problem
came to surface and made nephrologists aware of an impor-
tant contributor to morbidity and mortality. Cardiovascular
calcification in CKD may present as very different, hetero-
geneous conditions, such as medial calcification of large
arteries (Figure 1), advanced calcification of intimal athero-
sclerotic plaques, heart valve calcification (Figure 2), or
as calcific uremic arteriolopathy (calciphylaxis; Figure 3).
The former three entities often occur in parallel and are
highly prevalent in patients with advanced renal failure.
Calciphylaxis, in contrast, is a rare condition.
The aim of the present review is to provide an overview
about landmark developments in the last decade in the
context of what is nowadays called CKD–mineral and bone
disorders (CKD–MBDs). CKD–MBD is a term summarizing
mineral abnormalities, bone disease, and cardiovascular
disease associated with CKD. The list of 20 publications
presented in this review does not claim to cover all decisive
innovations. However, regarding pathophysiology, clinical
findings, and patient care, these selected articles represent
landmark publications to our personal understanding. We
are inviting the reader to follow us on that journey through
time that chronologically lists milestones in our under-
standing of CKD–MBD in general and uremic vascular
disease in particular.
THE YEARS 2000–2004
A publication by Goodman et al. in the New England Journal
of Medicine1 highlighted impressively the extent of acceler-
ated cardiovascular calcification in severe (end-stage) CKD.
Measuring coronary artery calcification by electron-beam or
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multislice computed tomography later became the gold
standard for non-invasive coronary artery calcification
assessment. The study showed that in adolescence, dialysis
patients have already developed significant amounts of
coronary artery calcification. In some way as a by-product,
the publication by Goodman et al. provided some very
forward-looking data that would keep the nephrology world
busy in the upcoming years. The authors showed that very
young people with a presumably still-growing skeleton were
free of vascular calcification; this pointed toward the
importance of healthy bone for vascular health. In addition,
Goodman et al. presented evidence for the deleterious role
of calcium therapy with respect to vascular damage, as the
amount of calcium per day ingested by patients with
calcification was twice the amount of patients without
calcifications. With regard to the clinical picture of patients
with coronary artery calcification, the authors almost
incidentally mentioned that angina was absent—a finding
nowadays well recognized in clinical nephrology: the classic
uremic media calcification does not typically lead to acute
coronary plaque rupture. And last but not least, the authors
described that those patients with baseline calcification tend
to show progression over time, whereas those free of baseline
calcification were protected during follow-up. At present,
we know that baseline calcification is the single most impor-
tant risk factor for progressive calcification in renal patients.
We have not yet identified the underlying causes why some
patients are protected against calcifications over a long period
of CKD and even end-stage renal disease.
In the same year, Jono et al.2 provided seminal insights
into the pathophysiology of renal vascular disease. It was
clear that although standard cardiovascular risk factors
(so-called Framingham risk factors) were highly prevalent
in CKD patients, the overwhelming cardiovascular disease
burden in renal patients remained incompletely explained,
and therefore the search for alternative cardiovascular risk
factors started. Jono et al. later used a frequently applied
model for in vitro calcification induction: human vascular
smooth muscle cells cultured in media with variable concen-
trations of phosphate. Cultured vascular smooth muscle
cells showed a dose-dependent matrix deposition of calcium
with increasing phosphate concentrations in the medium.
In addition, this in vitro model also provided mechanis-
tic evidence of how this calcification process takes place.
Figure 1 |Distal peripheral artery with linear tram track
calcification on plane X-ray (69-year-old diabetic end-stage
renal disease patient).
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Figure 2 |Multislice computed tomography with aortic valve
calcification in a 71-year-old dialysis patient. LA, left atrium;
LV, left ventricle; RA, right atrium; RV, right ventricle.
Figure 3 |Ulcerative calciphylaxis (61-year-old female end-
stage renal disease patient).
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The experiments by Jono et al. contributed substantially to the
model of an ‘active calcification process’. The term ‘active’ refers
to two issues: first, these experiments showed that intracellular
uptake of phosphate via a sodium–phosphate cotransporter
(type III sodium-dependent phosphate cotransporter, Pit-1)
was a prerequisite for calcification induction. Second, the gene
expression profile of human aortic smooth muscle cell changed
toward an increase of osteoblastic differentiation markers, a
process later referred to as osteoblastic transdifferentiation. The
work by Jono et al. and comparable data have substantially
changed our attitude toward hyperphosphatemia: nephro-
logists recognized the need to fight hyperphosphatemia not just
because it promotes hyperparathyroidism, but also because of
its direct negative health effects.
In 2001, Blacher et al.3 published a prospective study in
110 dialysis patients in whom the authors correlated the
amount of baseline vascular calcification (as assessed by
ultrasonography at four different anatomic sides) with
survival during a period of more than 4 years of follow-up.
Although critics could have argued that uremic vascular
calcification might be harmless, the data derived from
Blacher et al. clearly certified that vascular calcification is a
‘dose-dependent’ predictor of increased mortality among
dialysis patients. Therefore, early in that decade it became
clear that there is a link between disturbances of mineral
metabolism, uremic vascular disease, and poor outcome.
Whereas in the 1990s our therapeutic armamentarium
against hyperphosphatemia was limited to calcium- or
aluminum-containing phosphate binders, the next decade
developed an interesting alternative: the calcium- and
aluminum-free phosphate binders, of which sevelamer was
the first representative. The Treat-to-Goal (TTG) Study by
Chertow et al.4 was much talked about in clinical and basic
science communities, as it provided evidence that calcium
avoidance might help in controlling vascular calcification for
the first time. These data were a strong stimulus for further
scientific activities in the following years, and the kick-off
for a long-lasting vigorous and still ongoing ‘binder debate’.
At present, it is still not completely clear at what time which
binder substance is optimal for which patient, and economic
aspects need to be taken into account. Although uncritical
demonization of calcium therapy may not be justified, the
TTG Study contributed a lot to our currently cautious
handling of calcium dosage that has become standard in
modern CKD–MBD therapy.
The overwhelming amount of precalcifying factors in
uremia, such as hyperphosphatemia, however, is just one side
of the coin. Under physiological conditions, the tendency to
develop vascular calcification is counterbalanced by calcifica-
tion inhibitors. Serum fetuin-A is one of the extensively
studied calcification inhibitors that has gained substantial
interest in the last decade. Its importance for cardiovascular
health in dialysis patients was underlined by a study by
Ketteler et al.5 This study revealed an independent negative
effect of low serum fetuin-A levels upon survival in dialysis
patients. These data clearly point toward the importance of a
well-preserved balance of procalcifying and anticalcifying
factors for the maintenance of vascular health.
Preserving cardiovascular health and improving outcome
for CKD and dialysis was an important issue in the last
10 years. The publication by Teng et al.6 about survival
benefits of dialysis patients treated with paricalcitol versus
those treated with calcitriol opened another novel perspective
in clinical nephrology. Starting with Teng et al. and similar
publications, there was not only a ‘binder debate’ but also
a ‘vitamin D debate’. Supporters of the novel vitamin D
receptor activators keep citing data about lower incidences
of hypercalcemia and lower mortality rates in studies with
paricalcitol. However, the latter data are all derived from
non-randomized, non-controlled, non-prospective studies,
and thus their power to provide evidence is disputable.
However, studies such as the large cohort presented by
Teng et al. were hypothesis generating and have added very
valuable stimuli to the discussion about potential health
benefits of (active) vitamin D in nephrology. Without these
and similar cohort data, scientific efforts would not have been
directed to the same degree toward positive vitamin D effects
on endothelial, cardiac, and vascular function. Thus, Teng
et al. contributed significantly to stimulate active research
in the field of pleiotropic vitamin D effects.
In the absence of high-quality randomized controlled
trials, large registry databases from dialysis facilities pro-
vide valuable information for fighting excess cardiovascular
mortality in dialysis patients. Two of these databases from
North America provided detailed insights into disturbances
in mineral metabolism and their association with reduced
outcome for dialysis patients in 2004 (refs 7, 8) (the Fresenius
database by Block et al.,7 representing a descriptive ultra-
large cohort study with 440,000 patients). The Fresenius
database confirmed the deleterious association between
hyperphosphatemia and increased mortality among hemo-
dialysis patients even after multivariable adjustments, with
an optimal outcome detected for serum phosphorus levels
between 4 and 5mg/dl. For example, the relative risk for
mortality for serum phosphorus in the range 5.5–6.0mg/dl
was 1.25 (1.18–1.33). In contrast to serum calcium levels,
where the association between increasing levels and mortality
was linear, the association with outcome for serum phosphate
was a U-shaped curve. Block et al.7 presented another finding
that deserves special attention: the overall high annual
mortality rate of 19.5% that makes clear that dialysis patients
remain a high-risk category, even in the new millennium.
Although much smaller in terms of patient number (n¼ 515),
the data from Stevens et al.8 add valuable information to
this interaction between mineral metabolism and survival.
They clearly demonstrated that the risk for mortality due to
particular calcium, phosphate, and parathyroid hormone
(PTH) values depends on dialysis vintage, as incident
patients carried a different mortality risk compared with
prevalent dialysis patients. Moreover, the relative risk for
hypercalcemia and hyperphosphatemia, respectively, was
modified by baseline PTH levels. The authors detected
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the worst outcome during follow-up in the subgroup of
patients with low PTH (o27.3 pmol/l), hypercalcemia
(42.5mmol/l), and hyperphosphatemia (41.78mmol/l).
They interpreted this finding as an expression of effects of
adynamic bone disease.
THE YEARS 2005–2010
A year later, Kestenbaum et al.9 contributed some fascinat-
ing data to the discussion about mineral metabolism and
outcome. They investigated the association between baseline
serum phosphorus levels and outcome in 3490 veterans.
These patients were not end-stage renal patients but mostly
had CKD stage 3 (mean age 71±10 years). The most
intriguing finding was a roughly linear relationship between
each 0.5mmol/l stepwise increase of baseline serum phos-
phate and mortality in patients who were not on dialysis.9
Transferring high-normal phosphate levels and mild hyper-
phosphatemia as mortality risk factor from patients with
end-stage renal disease to people with mild CKD may
potentially have enormous impact on cardiovascular disease
management and prevention in the future. However, some
crucial issues remain unsolved: is there a ‘safe’ serum
phosphate threshold level fitting for everyone? Is the link
between hyperphosphatemia and mortality directly causal,
or is hyperphosphatemia the surrogate for yet unidentified
risk conditions? Is the association between hyperphos-
phatemia and reduced survival mediated by cardiovascular
disease? Should we treat mild or even borderline hyper-
phosphatemia in patients with CKD? And finally, should
the intervention be via diet, pills, or both?
In parallel, Kestenbaum et al.9 confirmed data that serum
phosphate levels remain ‘normal’ until the glomerular
filtration rate dropped below B35ml/min; thus, compared
with increases in PTH and decreases in active vitamin D,
hyperphosphatemia is a late finding during progressive CKD.
The last decade provided the presumably definitive solution
to that discrepancy: the introduction of the Klotho/fibroblast
growth factor (FGF)-23 system to nephrology.10 We now
know that FGF-23, functioning through its receptor Klotho,
is a potent phosphaturic hormone that in parallel down-
regulates synthesis of active vitamin D. The evolution of
our knowledge about FGF-23 is fascinating. Approximately
10 years ago, FGF-23 publications were limited to osteology
journals (with regard to hypophosphatemic osteomalacia,
vitamin D-resistant rickets) and finally developed to a session-
filling topic during international nephrology congresses. There
is an ongoing debate about how to handle FGF-23 in modern
nephrology. We are convinced that FGF-23 will end up as
a reliable marker tool for phosphate metabolism; however,
we feel a lot of additional research is needed to clarify
whether FGF-23 exerts a direct role in cardiovascular disease
(‘the good, the bad, or the ugly’?).
Another milestone regarding CKD–MBD and potentially
fighting cardiovascular disease was the introduction of calci-
mimetics and the first promising results showing reduction of
extraosseous calcification in uremia.11 Cinacalcet is nowadays
one of the cornerstones of modern hyperparathyroidism
treatment. However, its effects may reach far beyond norma-
lization of biochemical abnormalities. Lopez et al.11 were
among the first to publish data from rodent experiments
showing that a calcimimetic agent can attenuate calcitriol-
induced vascular calcification and improve survival in uremic
animals, whereas both calcitriol and calcimimetic treatment
improved hyperparathyroidism. The nephrology community
most eagerly anticipates data from the Evaluation of Cinacalcet
Therapy to Lower Cardiovascular Events Trial investigating
the issue of how cinacalcet can reduce mortality in dialysis
patients.12
The time between 2000 and 2010 was characterized by
several intriguing innovations for CKD–MBD care including
the market approval of calcium-free, aluminum-free phos-
phate binders (see above). On the basis of very promising
data regarding a positive effect upon cardiovascular calcifica-
tion of sevelamer, a large prospective, randomized control
trial was initiated and finally published in 2007—the Dialysis
Clinical Outcomes Revisited (DCOR) Trial.13 It is well known
that the results of that trial failed to show a survival benefit
for patients treated with sevelamer hydrochloride compared
with those treated with calcium-containing phosphate
binders, and that only a post hoc subgroup analysis suggested
a survival benefit in elderly patients (hazard ratio 0.77; 95%
confidence interval, 0.61–0.96). What are the consequences of
these negative findings? Our conclusion is not that calcium-
containing phosphate binders are harmless. Three issues
contributed to the failure of sevelamer: first, underpowered
sampling; second, the relatively short period of follow-up;
and third, prevalent dialysis patients may simply include
too many individuals whose cardiovascular conditions have
become so bad that they are resistant to such potentially
‘remodeling’ treatment strategies. We support the view that
the multifactorial cardiovascular risk factor concert that is
active in dialysis patients can hardly be overcome with a
single-tool intervention trial. Therefore, our personal conclu-
sion from all the available sevelamer data, including TTG
and DCOR,4,13 is that we should presumably initiate such
approaches early during the course of the disease (that is,
in CKD patients): prevention is preferable to treatment.
In 2007, another very interesting study (rodent experi-
ment) was published.14 Schurgers et al. reported on the
ability of high-dose vitamin K to regress warfarin-induced
medial elastocalcinosis. These findings are highly significant,
as they underline the negative effects of vitamin K antagonists
such as warfarin for arterial wall integrity (presumably due
to interference with the calcification-protective properties
of matrix Gla protein). Moreover, they demonstrate the
potential positive effects of vitamin K for the vessel wall
(anticalcification properties); last but not least, they show
that vascular calcification may regress, at least if the causal
agent is reversed. These and similar data have initiated an
intensive discussion upon potential threats of vitamin K
antagonist treatment in CKD and on the other potential
benefits of vitamin K substitution. The latter theory is about
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to be tested in a randomized controlled trial—the VitaVasK
Study. In the same year, Mizobuchi et al.15 once again drew
attention toward alternative active vitamin D forms with
different actions compared with calcitriol. The group could
show that the amount of vascular calcification induction in
uremic rats differs depending on the type of vitamin D
receptor activator, with calcitriol and doxercalciferol being
more deleterious than paricalcitol. What this study convin-
cingly taught us was that calcitriol and different vitamin D
receptor activators may not generally be accused of inducing
vascular calcification, but some usage of these substances may
actually be protective. If these experimental data represent
the missing piece of the puzzle regarding beneficial vitamin D
receptor activator survival effects according to data from
Teng et al. data6 has yet to be investigated.
The interplay between bone and vascular disease has
already been discussed. In the last decade, it became appa-
rent that bone health and vascular health are closely related
in uremia. London et al.16 have elegantly underlined this
hypothesis by investigating the relationship between bone
disease (assessed by bone biopsy), vascular disease (assessed
by measuring X-ray aortic calcification and pulse wave
velocity), and the cumulative intake of calcium in dialysis
patients. Their study revealed that, only in patients with
adynamic bone disease, there is an association between the
amount of calcium intake and the amount of aortic calci-
fication score, and pulse wave velocity, respectively. This
study again stimulated the belief in ‘modern’ CKD–MBD
therapy, that is, the need to avoid both overwhelming
calcium supply and oversuppression of bone metabolism.
We currently believe that only an intact bone compartment
for which an intact bone metabolism is required can buffer
divalent ions appropriately.
In her 2009 state-of-the-art review article, Giachelli17
summarized well the role of phosphate and vascular smooth
muscle cell in vascular calcification. We willingly adopt her
key messages: (1) vascular calcification is not a harmless
bystander, but is correlated with major cardiovascular events;
(2) vascular calcification is far more than a passive bio-
chemical precipitation process, but involves cellular processes
and genetic programs, and depends on the action of Pit-1,
the sodium-dependent phosphate cotransporter, because
only intracellular phosphate is capable of initiating dediffer-
entiation of vascular smooth muscle cell toward bone-like
cells. However, it is not phosphate alone that produces a pro-
calcifying environment. Shroff et al.18 conducted thorough
in vitro experiments studying the role of phosphate, calcium,
vesicle release, apoptosis, and the uremic milieu, respec-
tively, in stimulating vascular calcification. Together with
data presented by Giachelli,17 we now have a detailed picture
of which processes go on in vessels prone to calcification.
Importantly, calcium overload also contributes significantly
to in vitro calcification, and cellular structures previously
in contact with uremic milieu calcify much easier (faster
and at lower levels of calcium and phosphate) than normal
vessels do. Apoptosis, in part triggered by disturbances in
mineral metabolism, and uremia contribute to calcification;
the investigators underline the importance of vesicle release
due to apoptosis and calcium overload as the nidus for
calcification.18
Osteogenic transdifferentiation was a frequently investi-
gated and discussed topic in the time from 2000 to 2010. A
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Figure 4 | Time line for a decade with landmark publications about bone and vascular disease in patients with CKD. CAC, coronary
artery calcification; CKD, chronic kidney disease; ESRD, end-stage renal disease; FGF, fibroblast growth factor; KDIGO, Kidney Disease:
Improving Global Outcomes; K/DOQI, Kidney Disease Outcomes Quality Initiative; PTH, parathyroid hormone; TTG, Treat-to-Goal;
VDR, vitamin D receptor; VSMC, vascular smooth muscle cell.
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very recent study by Roman-Garcia et al.19 elegantly
investigated the bone–vascular axis and supported the
previously generated hypothesis that there is a close link
between disturbed bone metabolism and the occurrence of
vascular calcification. In short, in parallel with the reduction of
bone mass, ectopic (vascular) calcification is promoted. It is
our view that understanding the bone–vascular axis may help
identify future treatment options of uremia-related vascular
disease, as the saying ‘treat the bone to cure the vessels’ may
prove to be true.20 How can we prevent the process of calcium
deposition being blocked in bones yet progressing in vessels?
The continuous and overwhelming increase in our under-
standing of CKD–MBD in general, and uremic vascular disease
in particular, within the last 10 years makes it extraordinarily
difficult to formulate a simple closing remark. We finally point
toward two landmark guideline publications: the Kidney
Disease: Improving Global Outcomes (KDIGO) 2009 (ref. 21)
and the Kidney Disease Outcomes Quality Initiative (K/DOQI)
2003 (ref. 22) guidelines. Whereas K/DOQI tended to
formulate clear suggestions even if evidence was disputable,
KDIGO was a very cautious and diffident guideline, often
stressing the lack of clear evidence in CKB–MBD treatment.
We have presented 20 scientifically outstanding publications
to guide the reader through a decade of continuous develop-
ments (Figure 4). In accordance with KDIGO, we feel that,
regardless of how convincing these data appear, the next
priorities are to perform prospective, randomized interven-
tional trials to explore the optimization of treatment for
CKD–MBD. These studies should aim at decisive basic
questions such as which target levels for calcium, phosphate,
and PTH for which patient group by which intervention
improves hard end points in CKD and end-stage renal
disease. We regard this as the key task for the current decade,
which got off to a promising start with the publication of the
ADVANCE Trial showing that the combination of cinacalcet
and low doses of vitamin D may slow the progression of
cardiovascular calcification in dialysis patients.23
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